Vanda Pharmaceuticals Inc VNDA
News
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
FDA Decision Due on Vanda Pharma's Gastroparesis Drug
Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet
Vanda Pharmaceuticals shares jump 30% after FDA approval of Fanapt for bipolar I disorder
Vanda Pharmaceuticals Shares Jump 17% After FDA Approved Fanapt for Bipolar I Disorder
Vanda Pharmaceuticals' Fanapt Gets FDA Approval for Bipolar I Disorder
Vanda Pharmaceuticals: FDA Rejects Hetlioz Expanded Label
Vanda Pharma Says FDA Identified Deficiencies in Hetlioz Review That Preclude Discussion of Labeling, Postmarketing Requirements
Vanda Pharma's Trade Secrets Suit Against FDA Moves Forward
Vanda Pharmaceuticals Shares Rise Premarket on FDA Review of Tradipitant
Vanda Pharma Says FDA Accepts New Drug Application for Tradipitant to Treat Gastroparesis